Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Population Genomic Screening Programs Market Forecast: What Value Will The Market Reach By 2030?
The size of the population genomic screening programs market has experienced rapid growth in recent years. This market is projected to expand from $3.91 billion in 2025 to $4.47 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.3%. Historically, this expansion has been driven by increased awareness of hereditary diseases, the implementation of newborn screening programs, advancements in sequencing technologies, growing government health initiatives, and the development of healthcare infrastructure.
The market for population genomic screening programs is projected to experience substantial expansion over the upcoming years. Its value is set to reach $7.7 billion in 2030, showing a compound annual growth rate (CAGR) of 14.6%. This anticipated growth during the forecast period stems from factors such as the broadening of adult and carrier screening initiatives, the incorporation of AI-based genomic analysis tools, connectivity with digital health platforms, a rising need for individualized medicine, and increased investment in population genomic research. Key developments expected in this period encompass comprehensive genetic risk evaluation across populations, linking with electronic health records (EHR), AI-powered variant interpretation, tailored preventive health schemes, and adherence to data security and privacy regulations.
Get A Free Sample Report With In-Depth Market Insights:
Population Genomic Screening Programs Market Industry Drivers: What’s Behind The Revenue Growth?
The increasing need for individualized healthcare approaches is anticipated to boost the expansion of the population genomic screening programs market. This approach, personalized medicine, customizes medical interventions and health choices according to a person’s genetic makeup, environmental factors, and lifestyle, aiming to enhance treatment efficacy and safety. Its rising uptake is propelled by developments in genomics and molecular diagnostics, allowing medical professionals to gain deeper insights into genetic differences and administer more accurate, focused therapies, thereby improving patient results and minimizing negative reactions. Population genomic screening programs are fundamental to the advancement of personalized medicine, as they identify genetic variations and risk factors linked to diseases within broad and varied populations. Such programs facilitate the early detection of disease risks, the categorization of patient groups, and the creation of customized prevention and treatment plans for individuals and for public health initiatives. As an illustration, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, stated that in 2023 the U.S. Food and Drug Administration (FDA) sanctioned 16 new personalized treatments for rare disease patients, an increase from six approvals in 2022. Consequently, the expanding demand for personalized medicine is fueling the growth of the population genomic screening programs market.
Population Genomic Screening Programs Market Segment Trends And Revenue Contributors
The population genomic screening programs market covered in this report is segmented –
1) By Program Type: Newborn Screening, Adult Screening, Carrier Screening, Pharmacogenomics, Other Program Types
2) By Program Model: National Screening Programs, Regional Screening Programs, Institution Based Screening, Direct To Consumer Screening
3) By Technology: Next Generation Sequencing, Microarray, Polymerase Chain Reaction, Other Technologies
4) By Application: Rare Disease Detection, Cancer Risk Assessment, Pharmacogenomics, Chronic Disease Prediction, Other Applications
5) By End-User: Hospitals, Research Institutes, Government Agencies, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By Newborn Screening: Rare Disease Screening, Metabolic Disorder Screening, Immunodeficiency Disorder Screening, Neurological Disorder Screening, Endocrine Disorder Screening
2) By Adult Screening: Hereditary Cancer Risk Screening, Cardiovascular Genetic Risk Screening, Neurodegenerative Disease Risk Screening, Preventive Health Risk Screening, Late Onset Genetic Disorder Screening
3) By Carrier Screening: Preconception Carrier Screening, Prenatal Carrier Screening, Expanded Carrier Screening, Recessive Disorder Carrier Screening, Population Based Carrier Screening
4) By Pharmacogenomics: Drug Response Prediction Testing, Adverse Drug Reaction Risk Testing, Dose Optimization Testing, Therapeutic Selection Testing, Medication Safety Testing
5) By Other Program Types: Polygenic Risk Assessment Programs, Predictive Genomic Health Programs, Preventive Genomic Screening Programs, Population Risk Stratification Programs, Research Based Genomic Screening Programs
#Population Genomic Screening Programs Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies operating in the population genomic screening programs market are concentrating on developing innovative solutions, such as hereditary risk assessment, to facilitate the early identification of genetic predispositions, guide personalized prevention strategies, and enhance long-term health outcomes. Hereditary risk assessment involves evaluating an individual’s probability of developing specific genetic disorders or diseases, based on their inherited genetic variants and family medical history. For instance, in November 2023, Helix OpCo, LLC, a US-based population genomics and clinical technology company, partnered with Cone Health, a US-based not-for-profit network of healthcare providers, to launch a population genomics initiative aimed at advancing precision medicine in North Carolina. This program utilizes Helix’s comprehensive platform to furnish actionable precision medicine insights, thereby enabling earlier interventions, fostering community wellness efforts, and improving health equity across Alamance, Forsyth, Guilford, Rockingham, and Randolph counties and beyond.
Population Genomic Screening Programs Market Industry Leaders And Competitive Landscape
Major companies operating in the population genomic screening programs market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Illumina Inc., Natera Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Fulgent Genetics Inc., Ambry Genetics Corporation, Pacific Biosciences of California Inc., Color Genomics Inc., Helix OpCo Inc., Personalis Inc., CENTOGENE N.V., ProPhase Labs Inc., DNAnexus Inc., Genomics England Limited, Eurofins Genomics Germany GmbH, Sema4 Inc., Mapmygenome India Private Limited, Gencove Inc.
View The Full Population Genomic Screening Programs Market Report:
Population Genomic Screening Programs Market Regional Analysis And Top Geography
North America was the largest region in the population genomic screening programs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the population genomic screening programs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
